|
101
|
|
|
102
|
|
|
103
|
Psoriasis and Cardiovascular Risk: Strength in Numbers, Part II. J Invest Dermatol 2011. [DOI: 10.1038/jid.2011.32 order by 1#] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
|
104
|
|
|
105
|
Gelfand JM, Mehta NN, Langan SM. Psoriasis and cardiovascular risk: strength in numbers, part II. J Invest Dermatol 2011; 131:1007-10. [PMID: 21494241 PMCID: PMC3426317 DOI: 10.1038/jid.2011.32] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The Psoralen plus Ultraviolet-A (PUVA) cohort study has been a tremendous success in determining how a novel treatment (i.e., PUVA) affects the long-term risk of keratinocyte carcinoma. The ability to follow patients from the initial multicenter clinical trial for more than three decades has been a remarkable achievement in dermatoepidemiology. In this issue, Stern and Huibregtse report results from the PUVA follow-up study and conclude that only patients with exceptionally severe psoriasis have an increased overall mortality risk and that there is no significant risk of cardiovascular mortality associated with psoriasis. The results are in contrast to a large and growing body of literature that suggests patients with more severe psoriasis have a clinically significant increased risk of mortality in general and cardiovascular disease in particular. In addition, the authors found no association between severe psoriasis and obesity or between obesity and cardiovascular mortality, despite extensive literature establishing these associations. Basic principles of epidemiological study design may explain these discrepancies. Ultimately, however, randomized clinical trials will be necessary to determine whether severe psoriasis is in fact a "visible killer," as four decades ago (after many years of controversy) hypertension was recognized to be a "silent killer."
Collapse
Affiliation(s)
- Joel M Gelfand
- Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
| | | | | |
Collapse
|
|
106
|
|
|
107
|
|
|
108
|
|
|
109
|
|
|
110
|
|
|
111
|
|
|
112
|
|
|
113
|
Psoriasis and Cardiovascular Risk: Strength in Numbers, Part II. J Invest Dermatol 2011. [DOI: 10.1038/jid.2011.32 order by 1-- gsiz] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
|
114
|
|
|
115
|
|
|
116
|
Gelfand JM, Mehta NN, Langan SM. Psoriasis and Cardiovascular Risk: Strength in Numbers, Part II. J Invest Dermatol 2011. [DOI: 10.1038/jid.2011.32 order by 1-- qoen] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
117
|
|
|
118
|
|
|
119
|
Psoriasis and Cardiovascular Risk: Strength in Numbers, Part II. J Invest Dermatol 2011. [DOI: 10.1038/jid.2011.32 and 7519=7519-- zdta] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
|
120
|
|
|
121
|
|
|
122
|
|
|
123
|
|
|
124
|
Gelfand JM, Mehta NN, Langan SM. Psoriasis and Cardiovascular Risk: Strength in Numbers, Part II. J Invest Dermatol 2011. [DOI: 10.1038/jid.2011.32 and 7519=7519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
125
|
|
|
126
|
Gelfand JM, Mehta NN, Langan SM. Psoriasis and Cardiovascular Risk: Strength in Numbers, Part II. J Invest Dermatol 2011. [DOI: 10.1038/jid.2011.32 and (select (case when (3353=3353) then null else ctxsys.drithsx.sn(1,3353) end) from dual) is null] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
127
|
|
|
128
|
|
|
129
|
|
|
130
|
|
|
131
|
|
|
132
|
|
|
133
|
|
|
134
|
Gelfand JM, Mehta NN, Langan SM. Psoriasis and Cardiovascular Risk: Strength in Numbers, Part II. J Invest Dermatol 2011. [DOI: 10.1038/jid.2011.32 rlike (select (case when (8475=9868) then 0x31302e313033382f6a69642e323031312e3332 else 0x28 end))-- zgnh] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
135
|
Gelfand JM, Mehta NN, Langan SM. Psoriasis and Cardiovascular Risk: Strength in Numbers, Part II. J Invest Dermatol 2011. [DOI: 10.1038/jid.2011.32 and (select (case when (3353=3353) then null else ctxsys.drithsx.sn(1,3353) end) from dual) is null-- anbs] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
136
|
Psoriasis and Cardiovascular Risk: Strength in Numbers, Part II. J Invest Dermatol 2011. [DOI: 10.1038/jid.2011.32 and 8219=5036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
|
137
|
|
|
138
|
Stern RS, Huibregtse A. Very Severe Psoriasis Is Associated with Increased Noncardiovascular Mortality but Not with Increased Cardiovascular Risk. J Invest Dermatol 2011; 131:1159-66. [DOI: 10.1038/jid.2010.399] [Citation(s) in RCA: 113] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
|
139
|
|
|
140
|
|
|
141
|
|
|
142
|
Gelfand JM, Mehta NN, Langan SM. Psoriasis and Cardiovascular Risk: Strength in Numbers, Part II. J Invest Dermatol 2011. [DOI: 10.1038/jid.2011.32 and 6441=6460-- mrmv] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
143
|
|
|
144
|
|
|
145
|
|
|
146
|
Psoriasis and cardiovascular risk: strength in numbers, part II. THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 2011. [PMID: 21494241 DOI: 10.1038/jid.2011.32";select count(*) from generate_series(1,32000000)--] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The Psoralen plus Ultraviolet-A (PUVA) cohort study has been a tremendous success in determining how a novel treatment (i.e., PUVA) affects the long-term risk of keratinocyte carcinoma. The ability to follow patients from the initial multicenter clinical trial for more than three decades has been a remarkable achievement in dermatoepidemiology. In this issue, Stern and Huibregtse report results from the PUVA follow-up study and conclude that only patients with exceptionally severe psoriasis have an increased overall mortality risk and that there is no significant risk of cardiovascular mortality associated with psoriasis. The results are in contrast to a large and growing body of literature that suggests patients with more severe psoriasis have a clinically significant increased risk of mortality in general and cardiovascular disease in particular. In addition, the authors found no association between severe psoriasis and obesity or between obesity and cardiovascular mortality, despite extensive literature establishing these associations. Basic principles of epidemiological study design may explain these discrepancies. Ultimately, however, randomized clinical trials will be necessary to determine whether severe psoriasis is in fact a "visible killer," as four decades ago (after many years of controversy) hypertension was recognized to be a "silent killer."
Collapse
|
|
147
|
Gelfand JM, Mehta NN, Langan SM. Psoriasis and cardiovascular risk: strength in numbers, part II. THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 2011. [PMID: 21494241 DOI: 10.1038/jid.2011.32);select sleep(32)#] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The Psoralen plus Ultraviolet-A (PUVA) cohort study has been a tremendous success in determining how a novel treatment (i.e., PUVA) affects the long-term risk of keratinocyte carcinoma. The ability to follow patients from the initial multicenter clinical trial for more than three decades has been a remarkable achievement in dermatoepidemiology. In this issue, Stern and Huibregtse report results from the PUVA follow-up study and conclude that only patients with exceptionally severe psoriasis have an increased overall mortality risk and that there is no significant risk of cardiovascular mortality associated with psoriasis. The results are in contrast to a large and growing body of literature that suggests patients with more severe psoriasis have a clinically significant increased risk of mortality in general and cardiovascular disease in particular. In addition, the authors found no association between severe psoriasis and obesity or between obesity and cardiovascular mortality, despite extensive literature establishing these associations. Basic principles of epidemiological study design may explain these discrepancies. Ultimately, however, randomized clinical trials will be necessary to determine whether severe psoriasis is in fact a "visible killer," as four decades ago (after many years of controversy) hypertension was recognized to be a "silent killer."
Collapse
Affiliation(s)
- Joel M Gelfand
- Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
| | | | | |
Collapse
|
|
148
|
Gelfand JM, Mehta NN, Langan SM. Psoriasis and cardiovascular risk: strength in numbers, part II. THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 2011. [PMID: 21494241 DOI: 10.1038/jid.2011.32");declare @x char(9);set @x=0x303a303a332;waitfor delay @x--] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The Psoralen plus Ultraviolet-A (PUVA) cohort study has been a tremendous success in determining how a novel treatment (i.e., PUVA) affects the long-term risk of keratinocyte carcinoma. The ability to follow patients from the initial multicenter clinical trial for more than three decades has been a remarkable achievement in dermatoepidemiology. In this issue, Stern and Huibregtse report results from the PUVA follow-up study and conclude that only patients with exceptionally severe psoriasis have an increased overall mortality risk and that there is no significant risk of cardiovascular mortality associated with psoriasis. The results are in contrast to a large and growing body of literature that suggests patients with more severe psoriasis have a clinically significant increased risk of mortality in general and cardiovascular disease in particular. In addition, the authors found no association between severe psoriasis and obesity or between obesity and cardiovascular mortality, despite extensive literature establishing these associations. Basic principles of epidemiological study design may explain these discrepancies. Ultimately, however, randomized clinical trials will be necessary to determine whether severe psoriasis is in fact a "visible killer," as four decades ago (after many years of controversy) hypertension was recognized to be a "silent killer."
Collapse
Affiliation(s)
- Joel M Gelfand
- Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
| | | | | |
Collapse
|
|
149
|
Psoriasis and cardiovascular risk: strength in numbers, part II. THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 2011. [PMID: 21494241 DOI: 10.1038/jid.2011.32));select dbms_pipe.receive_message(chr(82)||chr(66)||chr(106)||chr(106),32) from dual--] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The Psoralen plus Ultraviolet-A (PUVA) cohort study has been a tremendous success in determining how a novel treatment (i.e., PUVA) affects the long-term risk of keratinocyte carcinoma. The ability to follow patients from the initial multicenter clinical trial for more than three decades has been a remarkable achievement in dermatoepidemiology. In this issue, Stern and Huibregtse report results from the PUVA follow-up study and conclude that only patients with exceptionally severe psoriasis have an increased overall mortality risk and that there is no significant risk of cardiovascular mortality associated with psoriasis. The results are in contrast to a large and growing body of literature that suggests patients with more severe psoriasis have a clinically significant increased risk of mortality in general and cardiovascular disease in particular. In addition, the authors found no association between severe psoriasis and obesity or between obesity and cardiovascular mortality, despite extensive literature establishing these associations. Basic principles of epidemiological study design may explain these discrepancies. Ultimately, however, randomized clinical trials will be necessary to determine whether severe psoriasis is in fact a "visible killer," as four decades ago (after many years of controversy) hypertension was recognized to be a "silent killer."
Collapse
|
|
150
|
Psoriasis and cardiovascular risk: strength in numbers, part II. THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 2011. [PMID: 21494241 DOI: 10.1038/jid.2011.32");select count(*) from generate_series(1,32000000)--] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The Psoralen plus Ultraviolet-A (PUVA) cohort study has been a tremendous success in determining how a novel treatment (i.e., PUVA) affects the long-term risk of keratinocyte carcinoma. The ability to follow patients from the initial multicenter clinical trial for more than three decades has been a remarkable achievement in dermatoepidemiology. In this issue, Stern and Huibregtse report results from the PUVA follow-up study and conclude that only patients with exceptionally severe psoriasis have an increased overall mortality risk and that there is no significant risk of cardiovascular mortality associated with psoriasis. The results are in contrast to a large and growing body of literature that suggests patients with more severe psoriasis have a clinically significant increased risk of mortality in general and cardiovascular disease in particular. In addition, the authors found no association between severe psoriasis and obesity or between obesity and cardiovascular mortality, despite extensive literature establishing these associations. Basic principles of epidemiological study design may explain these discrepancies. Ultimately, however, randomized clinical trials will be necessary to determine whether severe psoriasis is in fact a "visible killer," as four decades ago (after many years of controversy) hypertension was recognized to be a "silent killer."
Collapse
|